GlassScriptPhysician profile
Lin Xu
NPI 1790462414
$926.57
in general payments reported to CMS, 2019-2025
13 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $191 · 2024: $583 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908 · Education: $18.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.39 |
| Education | $18.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $186.43 | 2023-2025 | |
| Pfizer INC. | $129.71 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $101.10 | 2024 | Lifevest |
| Abbott Laboratories | $98.64 | 2024 | Emboshield Nav6 |
| Astrazeneca Pharmaceuticals LP | $88.55 | 2023-2025 | Brilinta |
| E.R. Squibb & Sons, L.L.C. | $84.07 | 2023-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.49 | 2023-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $46.69 | 2023-2024 | Xarelto |
| Boston Scientific Corporation | $46.30 | 2024 | Watchman Flx |
| Kiniksa Pharmaceuticals, LTD. | $38.02 | 2023 | Arcalyst |
| Novo Nordisk INC | $17.15 | 2024 | Rybelsus, Ozempic |
| Amgen INC. | $14.91 | 2024 | Repatha |
| Abiomed | $13.51 | 2024 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.